Willietta Gibson, Ph.D.
Affiliations: | 2007 | Medical University of South Carolina, Charleston, SC, United States |
Area:
Molecular Biology, Pathology, OncologyGoogle:
"Willietta Gibson"Parents
Sign in to add mentor| Charlton D. Donald | grad student | 2007 | MUSC | |
| (PAX2 transcriptional suppression of the putative tumor suppressor human beta defensin-1 in prostate cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gibson WJ, Hoivik EA, Halle MK, et al. (2016) The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics |
| Holst F, Hoivik EA, Gibson WJ, et al. (2016) Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports. 6: 25521 |
| Bandopadhayay P, Bergthold G, Nguyen B, et al. (2014) BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 912-25 |
| Franses JW, Drosu NC, Gibson WJ, et al. (2013) Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. International Journal of Cancer. Journal International Du Cancer. 133: 1334-44 |
| Bose SK, Gibson W, Giri S, et al. (2009) Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor. The Prostate. 69: 1334-42 |
| Bose SK, Gibson W, Bullard RS, et al. (2009) PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Molecular Immunology. 46: 1140-8 |
| Bullard RS, Gibson W, Bose SK, et al. (2008) Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Molecular Immunology. 45: 839-48 |
| Gibson W, Green A, Bullard RS, et al. (2007) Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Letters. 248: 251-61 |